Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291655 | 0.88 | IP6K1 (0.44) | BRD4 | |
| SCHEMBL29367083 | 0.88 | IP6K1 (0.44) | BRD4 | |
| SCHEMBL25934924 | 0.80 | P4HTM (0.35) | SOS1GSK3B | |
| SCHEMBL25926387 | 0.76 | BRD9 (0.42) | BRD4CYP2C19GSK3B | |
| SCHEMBL25771513 | 0.75 | ALDH1A1 (0.43) | CYP2C19ALDH1A1CYP1A2MAPTCYP2C9 | |
| SCHEMBL25926406 | 0.75 | BRD9 (0.42) | BRD4CYP2C19GSK3B | |
| SCHEMBL25771517 | 0.74 | CYP2C19 (0.42) | BRD4CYP2C19ALDH1A1CYP1A2MAPT | |
| SCHEMBL22291458 | 0.73 | BRD4 (0.33) | BRD4 | |
| SCHEMBL22291508 | 0.72 | CSNK2A1 (0.38) | BRD4 | |
| SCHEMBL16036052 | 0.72 | MAPT (0.42) | BRD4ALDH1A1MAPTKMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116322780-A | Compounds and uses thereof | 福宏治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4188447-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885CYP2C19 3845/4885ALDH1A1 1387/4885 |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885CYP2C19 3845/4885ALDH1A1 1387/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD4 42/4885CYP2C19 3845/4885ALDH1A1 1387/4885 |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | BRD9, BRWD1, BRD2 | BRD4 34/4885CYP2C19 1270/4885ALDH1A1 3268/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | BRD4 34/4885CYP2C19 1270/4885ALDH1A1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.